Successful cyclosporin A therapy for acquired amegakaryocytic thrombocytopenic purpura

Azuno, Yoichi; Yaga, Ken

doi:10.1002/ajh.10087

Cited by 11 publications

(3 citation statements)

References 4 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ATG was also reportedly effective in a case of AATP associated with a marked increase of T-activated suppressor cells (CD8 + /DR + ) [5]. Cyclosporine alone or in combination with ATG has been shown to be very effective in treatment of AATP [22][23][24]. In one of the reports of cyclosporine use, longitudinal follow-up revealed a relapsing and remitting disease course of AATP, which correlated with the dosing of cyclosporine [25].…”

Section: Treatmentmentioning

confidence: 96%

Acquired amegakaryocytic thrombocytopenic purpura

et al. 2006

View full text Add to dashboard Cite

show abstract

Section: Treatmentmentioning

confidence: 96%

Acquired amegakaryocytic thrombocytopenic purpura

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Anti-thymocyte globulin and cyclosporine, or the combination of both, are the mainstay treatment methods [4,5,6,7,8]. Variable treatment success of anti-thymocyte globulin and cyclosporine has been reported.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Amegakaryocytic Thrombocytopenia with Azathioprine

Chang

Tang

2011

Acta Haematol

View full text Add to dashboard Cite

Acquired amegakaryocytic thrombocytopenia (AAMT) is an entity characterized by severe thrombocytopenia with a significantly reduced number of megakaryocytes in the bone marrow. AAMT is rare and poorly defined. Therefore, standard treatment is not well established. In general, steroids are considered the frontline treatment while anti-thymocyte globulin and cyclosporine are reported to be effective in scattered reports. We report a case of AAMT which was successfully treated with azathioprine 3 mg/kg/day. The clinical bleeding tendency resolved after treatment for 4 weeks and complete remission was documented after 6 weeks. Azathioprine treatment for AAMT is low risk, convenient, and cost-effective. Our successful experience suggests that azathioprine is potentially the treatment of choice after steroid failure.

show abstract

“…Several case series have reported successful treatment with CSP as a monotherapy or in combination with other immunosuppressive agents [7, 17–19]. One case series documented the clinical course of 4 patients with AAT who were treated with ATG at 40 mg/kg/day for four days and then with an extended course of CSP [7].…”

Section: Managementmentioning

confidence: 99%

“Almost Bleeding to Death”: The Conundrum of Acquired Amegakaryocytic Thrombocytopenia

Brown

Babiker

Cantu

et al. 2014

Case Reports in Hematology

View full text Add to dashboard Cite

Acquired amegakaryocytic thrombocytopenia (AAT) is a rare hematological disorder causing severe thrombocytopenia and bleeding. Previous in vitro studies postulated both cell-mediated suppression of megakaryocytopoiesis in early megakaryocytic progenitor cells and humoral-mediated suppression by anti-thrombopoietin antibodies as possible etiologies of AAT. Patients with AAT usually present with severe bleeding and thrombocytopenia that is unresponsive to steroids and intravenous immunoglobulin (IVIG). Although standard guidelines have not been established for management of AAT, a few case reports have indicated a response to immunosuppressive treatment. The prompt recognition of this disease entity is essential in view of the substantial risk of morbidity and mortality from excessive bleeding. We report a case of AAT successfully treated with equine antithymocyte globulin (ATG) and cyclosporine (CSP).

show abstract

Successful cyclosporin A therapy for acquired amegakaryocytic thrombocytopenic purpura

Cited by 11 publications

References 4 publications

Acquired amegakaryocytic thrombocytopenic purpura

Acquired amegakaryocytic thrombocytopenic purpura

Successful Treatment of Amegakaryocytic Thrombocytopenia with Azathioprine

“Almost Bleeding to Death”: The Conundrum of Acquired Amegakaryocytic Thrombocytopenia

Contact Info

Product

Resources

About